ODE (Office of Device Evaluation) adds third deputy director in reorganisation:
This article was originally published in Clinica
Executive Summary
A reorganisation is in store for the Office of Device Evaluation (ODE) at the US FDA's Center for Devices and Radiological Health now that Susan Alpert has left to work at the FDA's food centre. The agency is advertising for a third deputy director to assist the new director, who has not yet been appointed. Dr Alpert shared the oversight responsibilities for the centre's six review divisions with Kimber Richter, deputy director for science and regulatory policy. The other deputy, Phil Phillips, handled regulatory matters. By adding a second clinical deputy, CDRH director David Feigal aims to relieve the next ODE director of some of the workload. ODE is responsible for product reviews.
You may also be interested in...
Common Regulatory Starting Point Means EU-UK Are On Track For Medtech MRA, Say German Firms
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
COVID-19 Vaccines Donated To Philippines Require Emergency Use Authorization
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Purespring Therapeutics: Pioneering Gene Therapy For Kidney Disorders
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: